Loading company…
Rampart Bioscience develops gene medicines and platforms for their development and delivery.
Rampart Bioscience develops gene medicines using proprietary development and delivery platforms, including a non-viral DNA delivery system for genetic diseases. Its work includes gene delivery, protein sciences and clinical translation. Founded in 2019, the company is based in the US and was at the Seed stage. In October 2023, it raised USD 85 million in Series A funding led by Forbion, with participation from HealthCap and RA Capital Management.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in